NAS:TSRO (USA) Also Trade In: Germany
Tesaro Inc $ 74.96 0 (0%)
Warning! GuruFocus has detected with TSRO. Click here to check it out.
Avg Vol (1m):
Market Cap $:
Enterprise Value $:
Current and historical daily P/E ratio for TSRO (Tesaro) from 2012 to Jul 12 2020. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Tesaro stock (TSRO) PE ratio as of Jul 12 2020 is 0. More Details
Tesaro PE Ratio (TTM) Historical Data
View and export this data going back to 2012. Start your Free Trial
Tesaro PE Ratio (TTM) Comparison
|Company||Market Cap(Mil)||PE Ratio (TTM)|
Compare SZSE:000990 NAS:FGEN LSE:BTG NAS:ONCE NAS:CBPO XKRX:128940 XKRX:215600 NAS:RARE NAS:BPMC NAS:UTHR HKSE:01548 NAS:ALLO NAS:ACAD XKRX:084990 HKSE:01801 HKSE:01530 NAS:ALKS SZSE:300759 XBRU:ARGX LSE:ABC
Tesaro is an oncology-focused biopharmaceutical company with a focus on developing treatments for cancer. Upon successful development and regulatory approval of any of its product candidates, the company intends to pursue commercialization in key product markets, including North America, Europe, and China. Tesaro is currently focused on commercializing products directly in North America, and directly or in partnership with established companies in Europe and China. The company's strategy is to identify, acquire, and develop promising drug candidates, and to commercialize cancer therapeutics that are potentially safer and more effective than existing treatments.